NewsRoom

Archives: Search / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012

2011201020092008

May 9, 2018
Data readouts in three programs expected in the second calendar quarter of 2018
Feb 13, 2018
Interim data further support potential of ME-344 to reverse resistance to antiangiogenic therapy
Feb 8, 2018
Pipeline advancement continues, including clearance of voruciclib IND by FDA and pracinostat Orphan Drug Designation by EMA
Dec 21, 2017
New Preclinical Studies Demonstrate Repression of MCL-1 and Sensitization to BCL-2 Inhibition in Diffuse Large B-Cell Lymphoma
Nov 22, 2017
Live Webcast from San Diego on November 30th
Nov 8, 2017
Quarter highlighted by dosing of first patient in pivotal Phase 3 study of pracinostat and exclusive license agreement for voruciclib
Nov 7, 2017
Live Webcast from New York on November 15th
Sep 19, 2017
Live Webcast from New York on September 26th
Sep 5, 2017
Clinical-Stage Asset in Validated Class of Drugs with Demonstrated Value
 

rss